VANCOUVER, BC, December 12, 2017 / – Reliq Health Technologies Inc. (TSXV:RHT or OTCQB:RQHTF) (“Reliq” or the “Company”), a technology company focused on developing innovative mobile health (mHealth) and telemedicine solutions for Community-Based Healthcare, is pleased to announce that it has entered into an engagement agreement with Canaccord Genuity Corp. and Gravitas Securities Inc. to act as co-lead agents on a commercially reasonable efforts basis in respect to a brokered private placement offering of up to 6,696,428 units (the “Units”) at a price of $1.12 per Unit for gross proceeds of up to $7,500,000 (the “Offering”) subject to completion of satisfactory due diligence. Each Unit will consist of one (1) common share in the capital of the Company (a “Share”) and one-half (1/2) transferable common share purchase warrant (each whole warrant, a “Warrant”), with each Warrant exercisable into one additional Share at a price of $1.75 for a period of two years from the date of closing. The Company intends to use the net proceeds of the offering for general working capital, product development and customer acquisition.

The Company has granted the Agents an over-allotment option (the “Over-Allotment Option”), which may be exercised in the Agents’ sole discretion and without obligation, exercisable in whole or in part and in one or more tranches at any time and from time to time prior to the closing of the Offering, to offer up to an additional 33% of the Units sold under the Offering, with the same terms and conditions as the Units.  This represents up to an additional 2,232,142 Units under the Offering, which would raise additional gross proceeds of up to $2,500,000, which would result in a total gross proceeds of up to $10,000,000 to be raised under the Offering.

“We are pleased to have the continued support of two of Canada’s leading independent brokerage firms,” said Dr. Lisa Crossley, CEO of Reliq.

The Company may pay a fees and commissions on the Offering within the amount permitted by the policies of the TSX Venture Exchange (the “Exchange”). Closing of the Offering is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, including the Exchange. All securities issued in connection with the Offering will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation. The Company anticipates that there may be insider participation in the Offering.



“Dr. Lisa Crossley”

CEO and Director


For further information contact:


Renmark Financial Communications Inc.

Laura Welsh:

Tel: (416) 644-2020 or (514) 939-3989


or CORE Capital Partners at 604-566-9233 or


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Statements Regarding Forward Looking Information

Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws.  All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”.


We caution you that such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.


Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including technology development, anticipated revenues, projected size of market, and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.


Reliq Health Technologies Inc. (the “Company“) does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, technology development and marketing activities, the Company’s historical experience with technology development, uninsured risks. Actual results may differ materially from those expressed or implied by such forward-looking statements.


SOURCE: Reliq Health Technologies Inc.